MCVEF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of -0.83% compared to Medicover AB's net margin of -25.62%. Medicover AB's return on equity of 3.71% beat BioArctic AB's return on equity of -23.03%.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than BioArctic AB, analysts believe Medicover AB is more attractive than BioArctic AB.

Medicover AB has a beta of -0.019, which suggesting that the stock is 101.926% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medicover AB has a quarterly dividend of $0.13 per share corresponding to a yield of 0.85%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 101.71% of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $580.5M, which are larger than BioArctic AB quarterly revenues of $7.4M. Medicover AB's net income of -$4.8M is lower than BioArctic AB's net income of -$1.9M. Notably, Medicover AB's price-to-earnings ratio is 106.92x while BioArctic AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.04x versus 107.08x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of -0.83% compared to Medicover AB's net margin of -213.29%. Medicover AB's return on equity of 3.71% beat Hansa Biopharma AB's return on equity of --.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than Hansa Biopharma AB, analysts believe Medicover AB is more attractive than Hansa Biopharma AB.

Medicover AB has a beta of -0.019, which suggesting that the stock is 101.926% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.431%.

Medicover AB has a quarterly dividend of $0.13 per share corresponding to a yield of 0.85%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 101.71% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $580.5M, which are larger than Hansa Biopharma AB quarterly revenues of $4.7M. Medicover AB's net income of -$4.8M is higher than Hansa Biopharma AB's net income of -$10M. Notably, Medicover AB's price-to-earnings ratio is 106.92x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.04x versus 9.81x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Abliva AB has a net margin of -0.83% compared to Medicover AB's net margin of --. Medicover AB's return on equity of 3.71% beat Abliva AB's return on equity of --.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Abliva AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than Abliva AB, analysts believe Medicover AB is more attractive than Abliva AB.

Medicover AB has a beta of -0.019, which suggesting that the stock is 101.926% less volatile than S&P 500. In comparison Abliva AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medicover AB has a quarterly dividend of $0.13 per share corresponding to a yield of 0.85%. Abliva AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 101.71% of its earnings as a dividend. Abliva AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $580.5M, which are larger than Abliva AB quarterly revenues of --. Medicover AB's net income of -$4.8M is lower than Abliva AB's net income of -$1.9M. Notably, Medicover AB's price-to-earnings ratio is 106.92x while Abliva AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.04x versus -- for Abliva AB. Usually stocks with elevated PS ratios are considered overvalued.

Oncopeptides AB has a net margin of -0.83% compared to Medicover AB's net margin of --. Medicover AB's return on equity of 3.71% beat Oncopeptides AB's return on equity of --.

Medicover AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncopeptides AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicover AB has higher upside potential than Oncopeptides AB, analysts believe Medicover AB is more attractive than Oncopeptides AB.

Medicover AB has a beta of -0.019, which suggesting that the stock is 101.926% less volatile than S&P 500. In comparison Oncopeptides AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medicover AB has a quarterly dividend of $0.13 per share corresponding to a yield of 0.85%. Oncopeptides AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicover AB pays 101.71% of its earnings as a dividend. Oncopeptides AB pays out -- of its earnings as a dividend.

Medicover AB quarterly revenues are $580.5M, which are larger than Oncopeptides AB quarterly revenues of --. Medicover AB's net income of -$4.8M is higher than Oncopeptides AB's net income of --. Notably, Medicover AB's price-to-earnings ratio is 106.92x while Oncopeptides AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicover AB is 1.04x versus 8.28x for Oncopeptides AB. Usually stocks with elevated PS ratios are considered overvalued.